吉西他滨联合长春瑞滨及地塞米松治疗复发难治性非霍奇金淋巴瘤疗效探讨.docVIP

精品论文 参考文献 吉西他滨联合长春瑞滨及地塞米松治疗复发难治性非霍奇金淋巴瘤疗效探讨 王银花（苏州市吴江区第一人民医院血液科 215200） 　　【摘要】目的：探讨吉西他滨联合长春瑞滨及地塞米松治疗复发难治性非霍奇金淋巴瘤的临床疗效。方法：随机将我院收诊的53 例复发难治性非霍奇金淋巴瘤患者分为观察组与对照组，观察组予以吉西他滨联合长春瑞滨及地塞米松治疗，对照组予以吉西他滨联合长春瑞滨治疗，比较两组患者的近期疗效及毒副反应。结果：观察组患者治疗总有效率63.0%，显著高于对照组的43.2%（Plt;0.05）；两组患者发生毒副反应情况无统计学差异（Pgt;0.05）。结论：吉西他滨联合长春瑞滨及地塞米松治疗复发难治性非霍奇金淋巴瘤疗效切实，毒副反应少有叠加。 　　【关键词】复发难治性；非霍奇金淋巴瘤；吉西他滨；长春瑞滨；地塞米松【中图分类号】 R2 【文献标号】 A 【文章编号】 2095-7165（2015）09-0442-02Curative effect discussion of intractable Non-hodgkins lymphoma treated withGemcitabine combined navelbine and dexamethasoneAbstract: Objective: To investigate Curative effect discussion of intractable Non-hodgkins lymphoma treated with Gemcitabine combined navelbine anddexamethasone. Methods: 53 cases of patients diagnosed as refractory non-hodgkins lymphoma in our hospital of were randomly divided into observationgroup and control group. The observation group was treated with Gemcitabine combined navelbine and dexamethasone, the control group was treatedwith Gemcitabine combined navelbine. Then the near future curative effect and adverse reaction of patients in the two groups were compared. Results:The total effective rate of patients in the observation group was 63.0%, which is significantly higher than 43.2% of the control group (Plt;0.05); the adversereaction of patients in the two groups had no statistical difference (Pgt;0.05). Conclusion: Curative effect on intractable Non-hodgkins lymphoma treatedwith Gemcitabine combined navelbine and dexamethasone is good, and the adverse reaction has rare superposition.Keywords: Refractory recurrence; Non-hodgkins lymphoma; Gemcitabine; Navelbine; Dexamethasone 　　为探讨吉西他滨联合长春瑞滨及地塞米松治疗复发难治性非霍奇金淋巴瘤的临床疗效，特选取我院收诊的53 例复发难治性非霍奇金淋巴瘤患者进行分组研究，具体如下。 　　1 资料与方法1.1 临床资料选取2011 年1 月-2014 年3 月我院收诊的53 例复发难治性非霍奇金淋巴瘤患者作为研究对象，所有患者均接受过一线方案化疗后复发或进展。纳入患者中男性29 例，女性24 例；年龄27-66 岁，平均（51.2plusmn;7.3）岁；非霍奇金淋巴瘤分布鼻咽28 例、肠道20 例、左胫骨3 例、右胫骨2 例；临床分期Ⅱ期11 例、Ⅲ期27 例、Ⅳ期15 例。经统计，两组患者的性别、年龄、分布及临床分期等临床资料无统计学差异（Pgt;0.05），具有可比性。 　　1.2 治疗方法对照组以吉西他滨联合长春